Empirical performance of the case-control method: Lessons for developing a risk identification and analysis system

Drug Safety

Volumn 36, Issue SUPPL.1, 2013, Pages

  Madigan, David ^a,d   Schuemie, Martijn J ^b,d   Ryan, Patrick B ^c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ACUTE LIVER INJURY; ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; EMPIRICISM; HEALTH CARE; HUMAN; INFORMATION PROCESSING; LIVER INJURY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL BLEEDING;

ACUTE KIDNEY INJURY; AREA UNDER CURVE; CASE-CONTROL STUDIES; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PROBABILITY; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84892947582     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0105-z     Document Type: Article

References (14)

1. Food and Drug Administration Amendments Act of 2007. Pub. L. 110-85, 21 U.S., 2007.
2. Woodward M. Epidemiology study design and data analysis. London: Chapman & Hall/CRC; 1999.
3. Agresti A. Categorical data analysis. Hoboken: Wiley-Interscience; 2002.
4. Breslow NE, Day NE. Statistical methods in cancer research. In: The analysis of case-control studies, vol. I. France: International Agency for Research on Cancer; 1993.
5. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkens; 2008.
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-83.
7. Ryan PB, Schuemie M. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf (in this supplement issue). doi:10.1007/s40264- 013-0110-2
8. Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf (in this supplement issue). doi:10.1007/s40264-013- 0102-2
9. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf (in this supplement issue). doi:10.1007/s40264-013-0097-8
10. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888-99.
11. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthr cartil OARS Osteoarthr Res Soc. 2002;10(4):290-6.
12. Maldonado G, Greenland S. Estimating causal effects. Int J Epidemiol. 2002;31(2):422-9.
13. Hofler M. Causal inference based on counterfactuals. BMC Med Res Methodol. 2005;5:28.
14. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-68.